SCHEMBL1023993

SCHEMBL1023993

Nc1cccc(C(=O)NCc2cccc(NC(=O)O)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 10/20 0.58
SENP2 Q9HC62 3/20 0.58
SENP5 Q96HI0 2/20 0.58
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
NAMPT P43490 2/20 0.53
ALDH1A1 P00352 2/20 0.52
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.52
CHRM3 P20309 1/20 0.52
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
SIRT2 Q8IXJ6 1/20 0.49
CFD P00746 1/20 0.49
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8395188 0.84 HDAC6 (0.69) ALDH1A1HPGDHTTCHRM3HDAC2
SCHEMBL13623005 0.82 SENP1 (0.52) SENP1SENP2SENP5LMNAMAPK1
SCHEMBL1075424 0.82 KCNK3 (0.64) ALDH1A1KDM4E
SCHEMBL4161846 0.82 HDAC6 (0.60) NAMPTALDH1A1HPGDCHRM3HDAC2
SCHEMBL1024076 0.80 ALDH1A1 (0.61) SENP1SENP2SENP5LMNAALDH1A1
SCHEMBL1024073 0.80 ALDH1A1 (0.61) SENP1SENP2SENP5LMNAALDH1A1
SCHEMBL3994203 0.80 SENP1 (0.69) SENP1SENP2LMNAMAPK1ALDH1A1
SCHEMBL7607244 0.79 PTGS1 (0.60) SENP1SENP2SENP5LMNAMAPK1
SCHEMBL4334746 0.79 MAOA (0.58) NAMPTALDH1A1HDAC2HDAC8HDAC6
SCHEMBL1075530 0.78 DDX3X (0.50) NAMPTALDH1A1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK SENP1 2867/4885SENP2 3357/4885SENP5 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.